AYTU - Aytu BioPharma, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

AYTU

AYTU BIOPHARMA, INC.

NASDAQ

$2.05

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$22.06 M

52w High$3.07

52w Low$1.80

Dividend Yield—

Frequency—

P/E-1.74

Volume5.62K

Shares Out.10.73M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joshua R. Disbrow

COMPENSATION 2026

Salary$590,000

Stock Awards$0

Incentive Plan Pay$247,800

All Other Comp.$0

Total$883,928

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 25, 2008

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$13.27M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2023-01-06	Reverse	1:20
2020-12-09	Reverse	1:10
2018-08-13	Reverse	1:20
2017-08-29	Reverse	1:20
2016-10-28	Reverse	1:12
2016-07-01	Reverse	1:12
2015-08-17	Reverse	41:500
2015-06-10	Reverse	41:500

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

33.47%

HOLDERS

TOP 8 OF 48 · RANKED BY POSITION SIZE

Nantahala Capital Management, LLC

1.1M sh

$2.83M

Stonepine Capital Management, LLC

891.9K sh

$1.68M

Awm Investment Company, Inc.

Crown Advisors Management, Inc.

145.0K sh

$395K

Two Sigma Investments, LP

122.0K sh

$332.99K

Renaissance Technologies LLC

95.1K sh

$178.83K

PRICE

$2.05 ▲ UP 0.00% (+$0.00)

OVERLAYS

About Aytu BioPharma, Inc.

https://aytubio.com ↗

Aytu Biopharma, Inc. develops and markets innovative prescription and consumer healthcare products, including ADHD treatments, allergy remedies, and sleep aids, serving the U.S. and international markets.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT AYTU BIOPHARMA, INC. IS KNOWN FOR

EXXUA™ (gepirone) extended-release tablets

EXXUA™, FDA-approved in 2025, is the first selective serotonin 5HT1a receptor agonist for adult MDD, marking Aytu BioPharma's entry into the $multi-billion U.S. antidepressant market with a novel treatment and distinct side effect profile.

COMPETITORS

COMPETITOR

Aytu BioPharma in 2025

SENTIMENT: + POSITIVE

PRODUCT LAUNCH · Q4 2025

Aytu BioPharma Launches EXXUA™, a Novel Antidepressant, Targeting the $22 Billion Major Depressive Disorder Market

In the fourth quarter of 2025, Aytu BioPharma announced the U.S. commercial launch of EXXUA™ (gepirone), the first and only FDA-approved 5HT1a agonist for the treatment of major depressive disorder (MDD) in adults. [9, 10, 11] This event was the culmination of a significant strategic shift for the company, which had recently restructured to focus on its prescription pharmaceuticals business and was positioned by analysts and the company as a pivotal growth driver and a potential "game-changer" in the treatment of depression. [5, 8, 17]

PRODUCT LAUNCH · Q4 2025 · IN PROGRESS

Aytu BioPharma Pivots to Central Nervous System Market with Commercial Launch of Antidepressant EXXUA™

Aytu BioPharma is making a significant strategic entry into the neurology market with the planned launch of its new antidepressant, EXXUA™, in the fourth quarter of 2025. This move diversifies the company's portfolio beyond its established ADHD and pediatric products and targets the substantial $22 billion U.S. market for major depressive disorder.